NMO (Aquaporin-4) IgG Test

The NMO (Aquaporin-4) IgG test is a specialised autoimmune neurological blood test that detects immunoglobulin G antibodies directed against aquaporin-4. Aquaporin-4, commonly abbreviated as AQP4, is a water-channel protein found in high concentration on astrocytes within the central nervous system. Astrocytes are supportive cells that help maintain the brain, spinal cord and optic nerves.

AQP4-IgG is an important biomarker for neuromyelitis optica spectrum disorder, commonly abbreviated as NMOSD. NMOSD is an autoimmune inflammatory disease that can affect the optic nerves, spinal cord, brainstem and selected areas of the brain. It was historically called neuromyelitis optica or Devic disease.

The test is particularly valuable because NMOSD can resemble multiple sclerosis while requiring a different treatment strategy. Detecting AQP4-IgG in the appropriate clinical setting supports early diagnosis and helps the neurologist select suitable treatment to reduce the risk of future attacks and accumulated neurological disability.

What Is Aquaporin-4?

Aquaporin-4 is a protein that forms water channels in cell membranes. It is especially abundant on the end-feet of astrocytes near blood vessels and other structures within the central nervous system. These channels contribute to water movement, fluid balance and normal neurological function.

In AQP4-IgG-positive NMOSD, the immune system mistakenly produces antibodies against this protein. When these antibodies bind to aquaporin-4, they can activate inflammatory pathways and damage astrocytes. This process may subsequently injure myelin, the protective covering around nerve fibres, and disrupt neurological function.

Because the primary autoimmune target is located on astrocytes, NMOSD is considered an autoimmune astrocytopathy rather than simply another form of multiple sclerosis. This biological difference contributes to differences in clinical presentation, prognosis and treatment.

What Is Neuromyelitis Optica Spectrum Disorder?

Neuromyelitis optica spectrum disorder is a rare autoimmune disease of the central nervous system. It commonly causes attacks of optic neuritis and transverse myelitis. It may also affect the area postrema in the lower brainstem, producing otherwise unexplained persistent nausea, vomiting or hiccups.

The disease frequently follows a relapsing course. Individual attacks may be severe and can cause substantial visual loss, weakness, sensory loss, bladder dysfunction or other disability. Early recognition is important because preventive immunotherapy can reduce the likelihood of additional attacks.

Common Clinical Presentations

A doctor may consider AQP4-IgG testing when a patient develops one or more characteristic neurological syndromes, including:

• Optic neuritis causing eye pain, blurred vision, colour-vision changes or loss of vision.
• Acute transverse myelitis causing weakness, numbness, sensory changes or bladder and bowel dysfunction.
• A long spinal cord lesion extending across several vertebral segments on MRI.
• Area postrema syndrome with persistent unexplained hiccups, nausea or vomiting.
• An acute brainstem syndrome involving swallowing, eye movement, balance or other functions.
• Selected diencephalic or cerebral syndromes with characteristic MRI abnormalities.

These symptoms can occur in several neurological disorders. AQP4-IgG testing is used with neurological examination and MRI findings rather than as a substitute for clinical evaluation.

Why Is the AQP4-IgG Test Performed?

The test is mainly used to support the diagnosis of NMOSD, identify autoimmune AQP4 channelopathy and help distinguish NMOSD from multiple sclerosis or other demyelinating diseases. Correct classification is clinically important because therapies that are appropriate for multiple sclerosis may be ineffective or unsuitable for AQP4-IgG-positive NMOSD.

A positive result in a patient with a compatible core neurological syndrome is highly supportive of NMOSD after reasonable alternative diagnoses have been excluded. The neurologist uses the antibody result with the clinical history and imaging findings to determine whether established diagnostic criteria are met.

Difference Between NMOSD and Multiple Sclerosis

NMOSD and multiple sclerosis can both cause optic neuritis, spinal cord inflammation and brain lesions. However, they differ in their immune targets, typical imaging patterns, clinical course and optimal treatment. NMOSD attacks may be particularly severe and can cause significant disability after relatively few episodes.

AQP4-IgG is generally not found in typical multiple sclerosis. Its detection can therefore help classify a patient whose presentation initially appears to be multiple sclerosis. CSF oligoclonal bands are common in multiple sclerosis but are often absent or transient in NMOSD, although this distinction is not absolute.

Difference Between AQP4-IgG Disease and MOGAD

Some patients with optic neuritis, transverse myelitis or an NMOSD-like presentation are negative for AQP4-IgG but positive for antibodies against myelin oligodendrocyte glycoprotein. This condition is known as MOG antibody-associated disease, or MOGAD.

MOGAD overlaps clinically with NMOSD but is considered a distinct autoimmune demyelinating disorder. Serum MOG-IgG testing using an appropriate cell-based assay may be recommended when AQP4-IgG is negative and clinical suspicion remains high.

Who May Need This Test?

A neurologist may recommend the NMO AQP4-IgG test for a patient with unexplained optic neuritis, extensive spinal cord inflammation, recurrent attacks affecting the optic nerves or spinal cord, area postrema syndrome or MRI findings suggestive of NMOSD.

Testing may also be appropriate when the diagnosis of multiple sclerosis is uncertain, when a patient has an unusually severe demyelinating attack or when symptoms do not follow a typical multiple sclerosis pattern. The decision to order the test should be based on clinical assessment.

Sample Requirements

Serum obtained from venous blood is generally the preferred sample for AQP4-IgG testing. Blood may be collected into a red-top tube or serum separator tube according to the laboratory's protocol. After clotting, the sample is centrifuged and serum is separated into an appropriate transport container.

Although AQP4-IgG can be tested in cerebrospinal fluid by selected laboratories, serum testing is usually more sensitive and is generally sufficient. CSF testing adds little sensitivity when an appropriate serum cell-based assay has been performed. Patients should confirm the specimen requirement with Focus Diagnostics before collection.

Is Fasting Required?

Fasting is generally not required for the NMO AQP4-IgG test. Patients may usually eat, drink water and take regular medicines unless their doctor gives different instructions or other tests being collected at the same time require fasting.

The doctor and laboratory should be informed about corticosteroids, plasma exchange, intravenous immunoglobulin, rituximab and other immunosuppressive or antibody-targeted treatments. These therapies may reduce circulating antibody concentrations and can occasionally contribute to a negative result despite genuine disease.

Best Time for Testing

When clinically possible, serum testing is often most informative during or close to an untreated neurological attack and before immunosuppressive treatment, plasma exchange or B-cell-targeted therapy begins. However, urgent treatment must never be delayed solely to obtain the antibody test.

If an initial result is negative but clinical suspicion remains strong, the neurologist may recommend repeat testing during a subsequent attack or before certain therapies. Repeat testing should use a sensitive and specific cell-based method whenever possible.

How Is AQP4-IgG Detected?

Cell-based assays are preferred for detecting AQP4-IgG because they present aquaporin-4 in a form resembling its natural expression on a cell membrane. Depending on the laboratory, detection may involve indirect immunofluorescence or fluorescence-activated cell sorting, also called flow cytometry.

The patient's serum is exposed to cells expressing aquaporin-4. If specific antibodies are present, they bind to the target protein. A fluorescently labelled secondary antibody allows the laboratory to detect this binding. Positive specimens may undergo additional titration or confirmatory evaluation according to the testing algorithm.

Cell-based methods generally provide better sensitivity and specificity than older enzyme-linked immunosorbent or tissue-based methods. The method used should be considered when evaluating a low-positive, negative or unexpected result.

Understanding the Test Result

The report typically states whether AQP4-IgG is positive or negative. Some laboratories may provide a titre or additional interpretive comment. The result must be correlated with the patient's core clinical syndrome, MRI findings and exclusion of alternative diagnoses.

Positive AQP4-IgG Result

A positive AQP4-IgG result obtained by a validated cell-based assay is strongly associated with NMOSD in a compatible clinical setting. It supports an autoimmune response targeting aquaporin-4 and can help distinguish NMOSD from multiple sclerosis.

A positive result does not describe the current severity of the disease or predict the exact timing of the next attack. The neurologist assesses symptoms, imaging and neurological function to develop a treatment and follow-up plan.

Negative AQP4-IgG Result

A negative result does not completely exclude NMOSD. Some clinically diagnosed patients do not have detectable AQP4-IgG. False-negative results may occur when the antibody level is low, when testing is performed during remission or after corticosteroids, plasma exchange, immunosuppressants or B-cell-depleting treatment.

When suspicion remains high, the doctor may review the assay method, repeat serum testing at an appropriate time, request MOG-IgG testing and evaluate the MRI and diagnostic criteria for seronegative NMOSD.

Low-Positive or Unexpected Results

Low-positive results obtained using less specific methods require cautious interpretation. Confirmation with a high-specificity cell-based assay may be appropriate, especially when the patient's symptoms and MRI findings are not typical of NMOSD.

Diagnosis should never be based solely on an isolated antibody report without a compatible neurological syndrome. The possibility of an alternative inflammatory, infectious, vascular, nutritional or structural disorder must be considered.

Additional Investigations

AQP4-IgG testing may be combined with:

• Serum MOG-IgG antibody testing.
• MRI of the brain, optic nerves and spinal cord.
• Ophthalmological examination and optical coherence tomography.
• Visual evoked-potential studies.
• CSF cell count, protein, glucose and oligoclonal bands.
• Tests for autoimmune, infectious, nutritional and vascular mimics.
• Other autoimmune neurological antibody panels when clinically appropriate.

The treating neurologist selects investigations according to the patient's presentation. Not every patient requires all of these tests.

Role in Treatment and Follow-Up

The detection of AQP4-IgG has important treatment implications because AQP4-IgG-positive NMOSD commonly follows a relapsing course. Acute attacks may be treated with high-dose corticosteroids, plasma exchange or other specialist-directed therapies. Long-term preventive immunotherapy may be recommended to reduce future attacks.

Antibody titres may change with disease activity and treatment, but they do not perfectly predict relapse. A falling or undetectable titre does not necessarily mean that treatment can be stopped. Treatment decisions should be based on the complete clinical course rather than the antibody value alone.

Benefits and Limitations

The major benefit of the test is its ability to identify a disease-specific autoimmune marker that can help distinguish NMOSD from multiple sclerosis. Early and accurate diagnosis allows the neurologist to select appropriate preventive treatment and may reduce disability caused by recurrent attacks.

Limitations include the possibility of a negative result in genuine disease and reduced antibody levels after immunotherapy. Assay methods differ in sensitivity and specificity. Testing is not intended for general screening and should be used for patients with an appropriate neurological presentation.

NMO AQP4-IgG Test at Focus Diagnostics

The NMO (AQUAPORIN 4)-IGG test is available under the pathology and bio-chemistry department at a listed price of ₹4,800. Patients should confirm the specimen type, required volume, collection tube, testing schedule and expected reporting time while booking.

Bring the neurologist's prescription, relevant MRI reports, previous antibody results and details of recent corticosteroid, plasma-exchange or immunosuppressive treatment. This information can assist the doctor in interpreting the result correctly.

Important Patient Instructions

• Fasting is generally not required unless otherwise instructed.
• Inform the doctor about current or recent immune therapy.
• Do not delay urgent neurological treatment for antibody collection.
• Do not interpret a positive result without neurological assessment.
• Discuss negative results with the neurologist if clinical suspicion remains high.

Medical Disclaimer

This information is intended for general education and does not replace professional medical consultation. AQP4-IgG testing supports the diagnosis of NMOSD but cannot independently evaluate symptoms or determine treatment. All results require interpretation by a qualified neurologist using clinical and imaging evidence.